The yearly MetaSystems Distributor Meeting (DM), brought into life in 2002 as a platform to gather all international partners of MetaSystems and other members of the global MetaSystems family, just ended last week. The DM is being organized in turns by MetaSystems Headquarters, MetaSystems USA (MGI), and MetaSystems Asia. Since MGI is celebrating its 25th anniversary in 2018 they decided to choose a special location: Nassau, The Bahamas!
- Order Number
- Package Size
- 100 µl
The XL 6q21/6q23/6cen locus-specific probe detects deletions in the long arm of chromosome 6. The green labeled probe hybridizes to a specific region at 6q21 including the SEC63 gene. The orange labeled probe hybridizes specifically to the MYB gene region at 6q23. A blue (aqua) labeled probe which hybridizes to the centromere of chromosome 6 functions as a reference probe.
The prognosis and clinical course of CLL is heterogeneous. Conventional banding techniques in CLL are hampered by the low mitotic index of the neoplastic cells. The introduction of interphase cytogenetics using fluorescent in situ hybridization (FISH) has greatly increased the sensitivity of cytogenetic analyses. With FISH abnormalities can be detected in more than 80 % of patients by using a 4-probe panel for the detection of trisomy 12q13-15 and deletions 13q14, 17p13, and 11q22-23. An additional 10 % of patients can be shown to carry a 6q21 deletion, 14q32 translocation, and partial trisomy 3q or 8q.
Deletions involving the long arm of chromosome 6 (6q) are among the most common structural aberrations leading to a loss of chromosomal material in lymphoproliferative disorders and non-Hodgkin's lymphoma (NHL). Two distinct regions, one at 6q21-22.1, the other at 6q23.3-25, have been found as minimal deleted regions in 6q- patients. A 6q deletion has also been found in a variety of other human malignancies as well, including breast carcinoma, malignant melanoma, renal cell carcinoma, salivary gland adenocarcinoma, ovarian carcinoma, acute lymphoblastic leukemia, and nodal non-Hodgkin's lymphomas.
- Acute Lymphoblastic Leukemia (ALL)
- Chronic Lymphocytic Leukemia (CLL)
- Non-Hodgkin Lymphomas (NHL)
Normal Cell: Two green (2G), two orange (2O), and two blue (2B) signals.
Aberrant Cell (typical results):
One green (1G), one orange (1O), and two blue (2B) signals, indicating a large 6q deletion including 6q21 and 6q23.
Aberrant Cell (typical results): Two green (2G), one orange (1O), and two blue (2B) signals, indicating a deletion in 6q23.
Aberrant Cell (typical results): One green (1G), two orange (2O), and two blue (2B) signals, indicating a deletion in 6q21.
- Stilgenbauer et al (1999) Leukemia 13:1331-1334
- Zhang et al (2000) Genes Chrom Canc 27:52-58
- Starostik et al (2000) Blood 95:1180-1187